Find a Physician

Email this profile
Portrait View Larger

Michael Amylon

Academic Appointments

  • Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus

Key Documents

Contact Information

  • Clinical Offices
    Pediatric Hematology-Oncology 725 Welch Rd MC 5798 Palo Alto, CA 94304
    Tel Work (650) 497-8953 Fax (650) 497-8101
  • Academic Offices
    Personal Information
    Email Tel (650) 723-5144

Professional Overview

Clinical Focus

  • Ped Hematology/Oncology
  • Hematology/Oncology

Academic Appointments

Professional Education

Fellowship: Stanford University School of Medicine CA (1981)
Residency: Stanford University School of Medicine CA (1979)
Internship: Stanford University School of Medicine CA (1977)
Board Certification: Hematology/Oncology, American Board of Pediatrics (1982)
Board Certification: Pediatrics, American Board of Pediatrics (1980)
Medical Education: Stanford University School of Medicine CA (1976)

Community and International Work



Scientific Focus

Current Research and Scholarly Interests

Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia. In the pediatric population, a variety of congenital disorders such as immunodeficiency syndromes, bone marrow failure states, hemoglobinopathies and inborn errors of metabolism can also be successfully treated with BMT. Identification of appropriate marrow donors (within or outside of the family) and the increasing use of autologous stem cells with or without purging have made this treatment approach available to more and more patients. Future studies will concentrate on control and prevention of graft-versus-host disease, ablation of malignant cells, and gene-transfer utilizing marrow stem cells as the vector.

T-cell Acute Lymphoblastic Leukemia and advanced stage Lymphoblastic Lymphoma are rare malignancies which affect pre-teen and teen-aged children with a male preponderance. These entities are closely related biologically, and probably represent different ends of a spectrum of T-cell malignancies. Treatment approaches taking advantage of the biological similarities of these entities have been successful in improving survival for affected children. Further studies of innovative approaches (immunotoxins, monoclonal antibody targeting, tumor antigen vaccination) as well as randomized clinical trials defining better chemotherapeutic regimens are ongoing. All patients entered in these protocols for treatment also participate in biologic studies utilizing molecular markers of minimal residual disease and classification studies at diagnosis and relapse including complete immunophenotyping and cytogenetics as well as classical morphology and histochemistry.


Publication tag cloud

Publication Topics

View All 74

Stanford Medicine Resources:

Footer Links: